Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Clinical Pharmacology Of Taxanes As Radiosensitizers And The Thiol-based Radioprotectant Amifostine

Robert T. Dorr
Published 1997 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Although many anticancer agents have been evaluated as radiosensitizing agents in cancer patients, none has demonstrated unequivocal clinical efficacy. Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been shown to enhance tumor cell response to ionizing radiation in cell culture studies. The pharmacokinetics and pharmacodynamics of paclitaxel in cancer patients receiving other highly metabolized drugs have not been well described and will be a key consideration in the development of the drug as a radiosensitizing agent. In addition, drug interaction studies demonstrate that administration sequence of paclitaxel with other chemotherapeutic agents, including cisplatin, doxorubicin, and cyclophosphamide, likely will affect its radiosensitizing efficacy. Other drugs that may affect paclitaxel radiosensitizing efficacy include corticosteroids and anticonvulsants; these interactions are particularly important in patients with central nervous system tumors, as is the question of whether paclitaxel can penetrate the blood-brain barrier. Overall, paclitaxel pharmacokinetics appear to favor radiosensitization, and results from an ongoing series of randomized trials should help define the drug's role in this setting. In contrast, amifostine, a sulfhydryl-containing agent, is currently being evaluated as a radioprotectant for normal tissues in patients who are receiving radiation therapy. Recent clinical trials have focused on amifostine's ability to reduce platinum-induced nephrotoxicity, although the drug was originally developed as a radioprotectant. Phase I clinical trials suggest that amifostine may be administered in much lower doses for radioprotectaon than those required for protection from platinuminduced nephrotoxicity. Amifostine pharmacokinetics support this finding; elimination of the drug may be dose dependent with clearance saturated at high doses, leading to increased risk of toxicity with no added radioprotectant benefit. Large randomized trials evaluating both paclitaxel as a radiosensitizer and amifostine as a radioprotectant are needed to make any firm conclusions regarding efficacy of either drug in modulating cancer therapy.
This paper references
Taxol sensitizes human astrocytoma cells to radiation.
R. Tishler (1992)
Investigation of taxol as a potential radiation sensitizer
H. Choy (1993)
Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction.
S. McDonald (1994)
Multidrug resistance mediated by P-glycoproteins.
A. Schinkel (1991)
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
E. Rowinsky (1991)
Salvage chemotherapy with paclitaxel for recurrent primary brain tumors.
M. Chamberlain (1995)
Radiation-drug interactions in the treatment of cancer
G. Sokol (1980)
A phase I study of WR-2721 in combination with total body irradiation (TBI) in patients with refractory lymphoid malignancies.
L. Coia (1992)
Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers.
W. Waugh (1991)
Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel.
L. Milas (1994)
Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721.
P. Calabro-Jones (1985)
Clinical importance of hepatic cytochrome P450 in drug metabolism.
M. Spatzenegger (1995)
A phase I trial of taxol given by a 6-hour intravenous infusion.
T. Brown (1991)
Use of radiation with or without WR‐2721 in advanced rectal cancer
T. Liu (1992)
Taxol: Mechanisms of Action and Resistance a
S. Horwitz (1993)
Radioprotectors in tumor radiotherapy: factors and settings determining therapeutic ratio.
L. Milas (1988)
Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
D. S. Sonnichsen (1994)
Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs.
I. Royer (1996)
Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721.
T. Wasserman (1981)
The clinical pharmacology of paclitaxel (Taxol).
E. Rowinsky (1993)
Pharmacokinetics of WR-2721.
L. Shaw (1988)
Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol.
J. W. Harris (1994)
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
G. Kemp (1996)
The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.
G. J. Schuurhuis (1990)
Taxol is converted to 7-epitaxol, a biologically active isomer, in cell culture medium.
I. Ringel (1987)
Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.
A. Rahman (1994)
The role of WR-2721 in radiotherapy and/or chemotherapy.
J. Yuhas (1980)
Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993.
E. Rowinsky (1994)
Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
L. Gianni (1995)
Promotion of microtubule assembly in vitro by taxol
PETER B. Schiff (1979)
Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
R. Klecker (1994)
Taxol sensitizes human ovarian cancer cells to radiation.
A. Steren (1993)
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.
C. Cordon-Cardo (1989)
Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel.
L. Milas (1995)
Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats.
G. LeBlanc (1992)
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.
M. Kennedy (1996)
Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer.
S. Berg (1995)
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
A. Sparreboom (1996)
Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck.
C. Leonard (1996)
Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721.
F. Valeriote (1982)
Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.
L. Gianni (1997)
Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
J. Yuhas (1980)
Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action.
D. Grdina (1995)
Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs.
D. Woodcock (1990)
In vitro studies of Taxol as a radiation sensitizer in human tumor cells.
J. Liebmann (1994)
The modification of melphalan toxicity in tumor bearing mice by S‐2‐(3‐aminopropylamino)‐ethylphosphorothioic acid (WR2721)
J. L. Millar (1982)
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
E. Friche (1990)
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.
F. Holmes (1996)
Phase I clinical and pharmacokinetic study of taxol.
P. Wiernik (1987)
Paclitaxel (Taxol) concentrations in brain tumor tissue.
J. J. Heimans (1994)
Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection.
G. Smoluk (1988)
WR-2721 as cytotoxic and radioprotective agent in treatment of murine lymphoma with total body irradiation.
L. Coia (1988)
Biological Characteristics of Some Improved Radioprotectors
D. Davidson (1980)
Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors.
M. Glantz (1995)
Hydrolysis of WR2721 by mouse liver cell fractions.
J. Nakamura (1987)
Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol).
J. Liebmann (1994)
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
P. Wiernik (1987)
Radiation protectors: the unexpected benefits.
D. Grdina (1989)
Final report on phase I trial of WR-2721 before protracted fractionated radiation therapy.
M. Kligerman (1988)
Protection by WR-2721 of human bone marrow function following irradiation.
L. Constine (1986)
Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
M. Huizing (1993)
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
W. Wilson (1994)

Semantic Scholar Logo Some data provided by SemanticScholar